---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008761"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:06:57.480335+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio discontinues sickle cell gene therapy nula-cel, begins strategic review, reports FY2022 net loss $101.1M

## Summary
- Discontinued development of nula-cel for sickle cell disease after serious adverse event (pancytopenia) in first dosed patient.
- Initiated process to evaluate strategic alternatives; corporate restructuring to preserve capital while conducting review.
- FY2022 net loss $101.1M ($1.84/share); cash and equivalents $283.6M as of Dec 31, 2022.
- Voluntarily paused Phase 1/2 CEDAR study of nula-cel in Jan 2023 due to treatment-related pancytopenia.
- Intends to continue research on early-stage non-genotoxic conditioning program toward potential development candidates.

## SEC filing metadata
- accession: 0000950170-23-008761
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/0000950170-23-008761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/grph-20230320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008761
- JSON: https://secwatch.observer/filing/0000950170-23-008761.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008761.txt

## Key facts
- Earnings Releases
  LENZ Therapeutics, Inc. reported Fourth quarter and fiscal year 2022 results: net income Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022, EPS $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022.
  - Period: Fourth quarter and fiscal year 2022
  - Net income: Net loss was $24.6 million for the fourth quarter of 2022; Net loss was $101.1 million for fiscal year 2022
  - EPS: $0.44 per basic and diluted share for the fourth quarter of 2022; $1.84 per basic and diluted share for fiscal year 2022
  - Result: reported results
  source text: Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815776/000095017023008761/0000950170-23-008761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.